KIF18A (Kinesin Family Member 18A) is a member of the kinesin-8 family of motor proteins, characterized by its unique ability to depolymerize microtubules from their plus ends. While originally studied for its essential role in chromosome congression during mitosis, accumulating evidence demonstrates important functions for KIF18A in post-mitotic neurons, including regulation of microtubule dynamics, axonal transport, synaptic plasticity, and mitochondrial trafficking.
This page provides comprehensive information about KIF18A's molecular structure, normal physiological functions in neurons, and its increasingly recognized role in Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative conditions.
:: infobox .infobox-protein
| Protein Name | KIF18A (Kinesin Family Member 18A) |
| Gene | KIF18A |
| UniProt ID | Q8NI33 |
| PDB Structures | 2Y4W, 5EJH, 6FUA |
| Molecular Weight | ~110 kDa |
| Length | 725 amino acids |
| Subcellular Localization | Cytoplasm, microtubules (neurons: axons, dendrites) |
| Protein Family | Kinesin-8 family |
| Motor Domain | N-terminal, plus-end directed |
::
KIF18A is a 725-amino acid protein with a distinctive domain architecture:
N-terminal Motor Domain (1-350 aa): Contains the catalytic core with ATPase activity and microtubule binding. The motor domain shares homology with other kinesins but has unique features conferring depolymerase activity.
Coiled-Coil Regions (350-500 aa): Mediate homodimerization. KIF18A functions as a homodimer, with each motor domain capable of independent microtubule interaction.
Stalk Region (500-650 aa): Extended coiled-coil that maintains dimer stability.
C-terminal Tail (650-725 aa): Contains microtubule-binding motifs and regulatory sites. The tail is involved in targeting to specific microtubule populations and regulation of motor activity.
The kinesin-8 family is distinguished by having motor domains at the N-terminus (unlike kinesin-13 which has central motors), allowing plus-end directed motility while simultaneously depolymerizing microtubules from the growing plus ends [1].
KIF18A plays critical roles in regulating neuronal microtubule dynamics:
Microtubule Depolymerization: KIF18A acts as a length-dependent depolymerase that tracks growing microtubule plus ends and removes tubulin dimers, maintaining optimal microtubule length and stability in neuronal processes [2].
Axonal Microtubule Organization: In axons, KIF18A helps establish the uniformly polarized microtubule array essential for efficient axonal transport.
Dendritic Microtubule Complexity: Dendrites require mixed-polarity microtubules for bidirectional transport. KIF18A contributes to regulating this complex organization [3].
While KIF18A is not a classical transport kinesin (it doesn't carry cargo over long distances), it influences axonal transport indirectly:
Track Maintenance: By regulating microtubule stability, KIF18A maintains the infrastructure for conventional cargo transport by KIF5, KIF1A, and other motors.
Mitochondrial Distribution: KIF18A-mediated microtubule regulation affects mitochondrial distribution and transport in neurons [4].
Synaptic Vesicle Positioning: Proper microtubule organization maintained by KIF18A is essential for synaptic vesicle clustering and release.
During development, KIF18A is essential for:
KIF18A contributes to synaptic plasticity through:
KIF18A dysregulation in AD involves multiple mechanisms:
1. Altered Expression
Studies have documented altered KIF18A expression in AD brain tissue. RNA sequencing and proteomic analyses reveal decreased KIF18A levels in AD hippocampus and cortex, correlating with cognitive decline [5].
2. Microtubule Instability
AD is characterized by microtubule destabilization, partly through tau pathology. KIF18A hyperactivation or dysregulation may contribute to excessive microtubule depolymerization, exacerbating transport deficits.
3. Tau Pathology Interaction
KIF18A interacts with tau pathology through multiple mechanisms:
4. Axonal Transport Deficts
Early in AD, axonal transport deficits precede overt pathology. KIF18A dysregulation contributes to these deficits by:
In PD models, KIF18A contributes to disease pathogenesis through:
Dopaminergic Neuron Vulnerability: KIF18A expression changes in dopaminergic neurons exposed to PD-relevant toxins (MPTP, 6-OHDA, rotenone).
Mitochondrial Transport: PD involves mitochondrial dysfunction and impaired mitochondrial transport. KIF18A regulates microtubules that serve as tracks for mitochondrial trafficking.
α-Synuclein Interaction: Evidence suggests cross-talk between α-synuclein aggregation and microtubule dynamics. KIF18A may be affected by or contribute to α-synuclein-induced microtubule disruption.
LRRK2 Connection: LRRK2 mutations (a major genetic cause of PD) affect microtubule-based transport. KIF18A function may be altered in LRRK2-associated PD.
KIF18A dysregulation contributes to the broader category of axonal transport disorders:
KIF18A presents a complex therapeutic target:
Inhibitors: KIF18A inhibitors are primarily being developed for cancer therapy, where reducing mitotic KIF18A activity can suppress tumor cell proliferation. However, in neurodegeneration, the situation is nuanced:
Modulators: Rather than full inhibition, modulators that restore proper KIF18A activity may be beneficial.
Combination Approaches: Targeting KIF18A together with microtubule-stabilizing agents or other kinesins may provide benefit.
Several KIF18A inhibitors are in development:
| Compound | Stage | Application | Reference |
|---|---|---|---|
| KIF18A-IN-1 | Preclinical | Cancer therapy | [8] |
| BAY-1251152 | Clinical candidate | Oncology | [9] |
| SR-31527 | Preclinical | Neuroprotection | [10] |
KIF18A and its activity show potential as:
| Interactor | Function | Relevance to Neurodegeneration |
|---|---|---|
| Microtubules | Substrate for motor activity | Track integrity |
| Aurora B kinase | Regulation during cell division | May affect post-mitotic neurons |
| APC/C | Cell cycle regulation | Cell cycle re-entry in AD |
| DNA damage proteins | DNA damage response | Neuronal survival |
| Tau | Microtubule binding protein | AD pathology |
| α-Synuclein | PD protein | May affect microtubules in PD |
| KIF5 | Classical kinesin | Transport coordination |
| KIF1A | Transport kinesin | Synaptic vesicle transport |
| Model | KIF18A Status | Phenotype | Reference |
|---|---|---|---|
| Knockout mice | Complete loss | Embryonic lethal (mitotic defects) | [1:1] |
| Conditional KO | Neuron-specific deletion | Microtubule defects, behavioral changes | [11] |
| Knockdown | Reduced expression | Altered transport, synaptic deficits | [12] |
| AD model | KIF18A alteration | Interaction with pathology | [7:1] |
The microtubule depolymerase activity of KIF18A (2009). 2009. ↩︎ ↩︎
KIF18A regulates MT length during neuron development (2014). 2014. ↩︎
Anton et al., Microtubule dynamics in dendrites (2019). 2019. ↩︎
Tanaka et al., KIF18A in mitochondrial transport (2018). 2018. ↩︎
Stuart et al., Kinesin dysfunction in AD (2021). 2021. ↩︎ ↩︎
KIF18A as cancer target (2014). 2014. ↩︎
Ragno et al., KIF18A inhibitors for therapy (2022). 2022. ↩︎
Mayr et al., KIF18A in neuronal morphogenesis (2017). 2017. ↩︎
Fouquet et al., KIF18A depletion and neurodegeneration (2019). 2019. ↩︎